![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Adis International Limited
Publisher: Adis International
ISSN: 1174-5886
Source: Drugs in R&D, Vol.9, Iss.3, 2008-01, pp. : 197-202
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Belimumab: Anti-BLyS Monoclonal Antibody; Benlysta™; BmAb; LymphoStat-B
Drugs in R&D, Vol. 10, Iss. 1, 2010-05 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Drugs in R&D, Vol. 3, Iss. 2, 2002-02 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Natalizumab: AN 100226, Anti-4 Integrin Monoclonal Antibody
Drugs in R&D, Vol. 5, Iss. 2, 2004-01 ,pp. :